Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Risk-adapted Donor Lymphocyte Infusion and Azacitidine for the Prevention of Hematologic Malignancy Relapse Following Allogeneic Stem Cell Transplantation

NCT02458235 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT02458235
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02458235 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Risk-adapted Donor Lymphocyte Infusion and Azacitidine for the Prevention of Hematologic Malignancy Relapse Following Allogeneic Stem Cell Transplantation
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Completed
Start date
June 2, 2015
Completion date
March 15, 2019
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoid leukemia, acute myelogenous leukemia, juvenile myelomonocytic leukemia, myelodysplastic syndrome